Merck Biopharma  announced it has entered into a partnership with a French subsidiary called HAPPYneuron, and now has an exclusive license to that company’s cognitive remediation training program for multiple sclerosis (MS). The program, a series of brain training games and exercises, will be made available to people needing it through Merck’s MSdialog platform. An e-Health…

With the Consortium of Multiple Sclerosis Centers (CMSC) 2016 fast approaching, Multiple Sclerosis News Today sat down with a man of far-reaching interest in multiple sclerosis (MS)  — Dr. Rick Munschauer, Vice President of Medical Affairs, Neurology and Immunology at…

An international research team recently reported that the web-based MSdialog app is being adopted by both multiple sclerosis (MS) patients and healthcare providers. The study is entitled “Patient and Physician Perspectives on MSdialog, an Electronic PRO Diary in Multiple Sclerosis” and was published in the journal…

Merck recently reported its intention to file for European registration of its product candidate for relapsing multiple sclerosis – Cladribine, a synthetic anti-cancer agent able to suppress the immune system. Cladribine causes relatively few side effects and results in very little non-target cell loss. Merck’s decision follows new findings and further characterization of…

Biopharmaceutical company Merck Serono, a division of Merck, recently awarded a total of €1 million to the five winners of the second annual Grant for Multiple Sclerosis Innovation (GMSI) at MS Boston 2014, the joint meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee…